drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-engineered T cells)
drug_description
Autologous, gene-engineered TCR-T cell therapy expressing an HLA-A*11:01–restricted T-cell receptor targeting mutant KRAS G12V on tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an HLA-A*11:01–restricted T-cell receptor that recognizes mutant KRAS G12V peptides presented on tumor cells. Antigen engagement activates the T cells to mediate targeted cytotoxicity (perforin/granzyme release and cytokine secretion), leading to selective killing of KRAS G12V–positive tumor cells.
drug_name
NW-301V
nct_id_drug_ref
NCT06478251